



Effective June 2, 2017, Cote Orphan LLC has been purchased and is now wholly owned by QuintilesIMS. All Cote Orphan personnel (including Dr Tim Cote) are being carried forward as employees now of "Cote Orphan, a QuintilesIMS Company". We are delighted to continue serving hundreds of orphan drug innovators with the absolute best in both orphan designations and review division regulatory affairs.

ENGLISH 简体中文 繁體中文